PDSB Earnings Prediction
The chart below shows how PDSB performed 10 days before and after its earnings report, based on data from the past quarters. Typically, PDSB sees a +4.81% change in stock price 10 days leading up to the earnings, and a -0.41% change 10 days following the report. On the earnings day itself, the stock moves by -1.02%. This data can give you a slight idea of what to expect for the next quarter's release.
PDSB Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
--
--
--
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
-0.29
-17.14%
26.09%
No Data Available
PDSB Earnings Analysis
PDS Biotechnology Corporation Common Stock Corporation (PDSB.O) Earnings Conference Call
Positive
Net Loss Improvement: PDS Biotech reported a net loss of approximately $10.7 million for Q3 2024, a slight decrease from a net loss of $10.8 million in Q3 2023, indicating improved financial performance year-over-year.
R&D Expense Increase: Research and development expenses increased to approximately $6.8 million for the three months ended September 30, 2024, up from $6.4 million for the same period in 2023, reflecting ongoing investment in clinical programs.
Operating Expenses Reduction: The overall operating expenses decreased to approximately $10.2 million for the three months ended September 30, 2024, down from $10.5 million for the same period in 2023, showcasing effective cost management.
Strong Cash Position: PDS Biotech's cash and cash equivalents totaled approximately $50 million as of September 30, 2024, providing a strong financial position to support ongoing operations and clinical trials.
Clinical Trial Progress: The company expects to initiate the first sites for the VERSATILE-003 trial in early 2025, indicating progress in their clinical development pipeline.
Negative
Quarterly Net Loss Comparison: The net loss for the quarter was approximately $10.7 million, or $0.29 per basic and diluted share, compared to a net loss of $10.8 million, or $0.35 per basic share for the three months ended September 30, 2023.
R&D Expense Increase: Research and development expenses increased to approximately $6.8 million for the three months ended September 30, 2024, up from $6.4 million for the three months ended September 30, 2023.
Operating Expenses Decrease: The overall operating expenses decreased to approximately $10.2 million for the three months ended September 30, 2024, down from $10.5 million for the three months ended September 30, 2023.
Net Interest Expense Increase: Net interest expenses increased to approximately $0.5 million for the three months ended September 30, 2024, up from $0.3 million for the three months ended September 30, 2023.
Cash Liquidity Decline: The overall cash and cash equivalents at September 30, 2024 totaled approximately $50 million, indicating a decrease in liquidity compared to previous quarters.
PDSB FAQs
How does PDSB typically perform around its earnings report dates?
Is PDS Biotechnology Corporation (PDSB) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
PDSB Earning Call Sentiment
PDS Biotechnology Corporation (PDSB) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
PDSB.O
-6.34%Positive
The earnings call reveals mixed signals. While there are promising clinical developments and a stable cash position, financial risks and competitive pressures pose challenges. The Q&A section shows confidence in ongoing trials, but also highlights regulatory and supply chain risks. The net loss remains consistent, and though there are operational cost reductions, increased R&D expenses and competitive pressures could offset these gains. Overall, the sentiment is balanced, leading to a neutral outlook for the stock price in the near term.
